Harnessing the power of evolution to develop life-changing medicines

Evolution is our platform.
Patients are our purpose.

Evolution has already honed molecules and mechanisms that overcome life-threatening conditions. This occurred over hundreds of millions of years of evolutionary time.

Elephants are resistant to cancer because their genomes contain dozens of copies of a tumor-suppressive gene (for reference, humans only have two copies).

An ancient Chinese tree holds innate, anti-cancer fighting properties that have been shown to effectively treat cancer.

Honeybee venom drills holes into red blood cells and upregulates part of the immune system that helps to attack cancer.

Hibernating bears avoid blood clots while not moving for months at a time by downregulating total body inflammation.

Bowhead whales live for over 200 years with natural ability to avoid cancer and keep their DNA-free from mutations.

At Peel, we translate these awe-inspiring discoveries into medicines for patients with life-threatening diseases. By applying our expertise in evolutionary biology with a deep understanding of how medicines function in the human body, we identify new targets and introduce evolutionary medicines as safe and efficacious treatments for people with devastating cancers and immune diseases.

The Peel R&D engine: Picking up where nature left off

At Peel Therapeutics, our technologies and expertise enable our company to deliver on the therapeutic potential of evolutionary outliers that circumvent disease.

Our team seeks the distinct molecules and genetic pathways in nature based on evolutionary discoveries that exceed what we’ve deemed biologically possible. We use our Darwin.AI™ proprietary discovery engine to identify new drug targets to develop. We are selective in the programs we move through our pipeline and our process includes assessing a potential asset’s impact on human physiology, efficacy and safety.

Our multidisciplinary R&D team includes experts in A.I., evolutionary biology, immunology, cancer research, protein and chemical engineering, drug delivery, clinical trials and medical practice to create a deep understanding that enables us to develop evolutionary medicines to have a lasting impact for patients.

  • Step 1

    Evolution of Solutions

    Over millions of years, nature evolves mechanisms to treat and prevent disease.

  • Step 2

    Concept Discovery

    Peel works with academic scientists and our Darwin Discovery engine to identify new targets in nature and demonstrate proof-of-concept in relevant disease models.

  • Step 3

    Asset Selection

    Peel selects drugs to in-license and targets to develop into evolutionary medicines from our Darwin Discovery engine prioritized by: alignment with our mission, interaction with human biology, impact on patient lives and likelihood of project success.

  • Step 4

    Optimization of Nature

    Peel’s R&D team works in-house and with third-party experts to engineer targets and formulate to maximize solubility, scalability, and bioavailability.

  • Step 5

    Development for Clinic

    Peel’s team works with CDMOs and CROs to produce all material and data required for regulatory approval to test the drug in human clinical trials.

  • Step 6

    Translation to Patients

    Peel’s clinical team works with CROs to bring our assets directly to patients in clinical trials to test safety and efficacy.

We are currently enrolling a Phase 1 Clinical Trial for chemotherapy resistant solid tumors

Visit Clinicaltrials.gov

Publications and Presentations

RecentPEEL-224EP53NTP

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

https://pubmed.ncbi.nlm.nih.gov/36733389/
Read more

Neonatal NET-Inhibitory Factor improves survival in the cecal ligation and puncture model of polymicrobial by inhibiting neutrophil extracellular traps

https://pubmed.ncbi.nlm.nih.gov/36733389/
Read more